Ítem
Solo Metadatos

Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema Pilot study of the Pan-American Collaborative Retina Study Group

Mostrar el registro sencillo de la publicación
dc.creatorArevalo, J. Fernandospa
dc.creatorGarcia-Amaris, Rafael A.spa
dc.creatorRoca, Jose A.spa
dc.creatorSanchez, Juan G.spa
dc.creatorWu, Lihtehspa
dc.creatorBerrocal, Maria H.spa
dc.creatorMaia, Mauriciospa
dc.creatorGroup, Pan-American Collaborative Retina Studyspa
dc.creator.OrganizationalPan-American Collaborative Retina Study Group (PACORES)
dc.date.accessioned2020-08-06T16:20:12Z
dc.date.available2020-08-06T16:20:12Z
dc.date.created2007-12spa
dc.description.abstractTo determine the feasibility, safety, and clinical effect of primary intravitreal bevacizumab (Avastin) in patients with cystoid macular edema (CME) after cataract surgery. Five institutions in Venezuela, Costa Rica, Puerto Rico, Peru, and Brazil. Twenty-eight eyes of 25 patients treated with at least 1 intravitreal injection of 1.25 mg or 2.50 mg of Avastin participated in this interventional retrospective multicenter study at 5 institutions from 5 countries. Baseline and follow-up visits included Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing, optical coherence tomography (OCT) imaging, and ophthalmoscopic examination. The mean follow-up was 32 weeks (range 24 to 52 weeks). Twenty eyes (71.4%) had improved best corrected visual acuity (BCVA) (R2 ETDRS lines), and no eye had worse visual acuity (R2 ETDRS lines). The BCVA remained stable in 8 eyes (28.6%). The mean baseline BCVA was 20/160 (logMAR Z 0.92) and the mean final BCVA, 20/63 (logMAR Z 0.50); the difference was statistically significant (P<.0001). The mean central macular thickness at baseline (466.3 mm; range 208 to 784 mm) decreased significantly (264.5 mm; range 176 to 513 mm) by the end of follow-up (P<.0001). Eight eyes (28.6%) required a second injection and 4 (14.3%), a third injection. The mean interval between injections was 13 weeks (range 5 to 26 weeks). No ocular or systemic adverse events were observed. Short-term results suggest that primary intravitreal Avastin is well tolerated in patients with pseudophakic CME. Treated eyes had a significant improvement in BCVA and decrease in macular thickness by OCT.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.jcrs.2007.07.046
dc.identifier.issnISSN: 0886-3350
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/25914
dc.language.isoengspa
dc.publisherLippincott Williams & Wilkins (LWW)spa
dc.relation.citationEndPage2105
dc.relation.citationIssueNo. 12
dc.relation.citationStartPage2098
dc.relation.citationTitleJournal of Cataract & Refractive Surgery
dc.relation.citationVolumeVol. 33
dc.relation.ispartofJournal of Cataract & Refractive Surgery, ISSN: 0886-3350, Vol.33, No.12 (December, 2007); pp.2098-2105spa
dc.relation.urihttps://journals.lww.com/jcrs/FullText/2007/12000/Primary_intravitreal_bevacizumab_for_the.35.aspxspa
dc.rights.accesRightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.accesoRestringido (Acceso a grupos específicos)spa
dc.sourceJournal of Cataract & Refractive Surgeryspa
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subject.keywordAgedspa
dc.subject.keywordAgedspa
dc.subject.keyword80 and overspa
dc.subject.keywordAngiogenesis Inhibitorsspa
dc.subject.keywordAntibodiesspa
dc.subject.keywordMonoclonalspa
dc.subject.keywordAntibodiesspa
dc.subject.keywordMonoclonalspa
dc.subject.keywordHumanizedspa
dc.subject.keywordBevacizumabspa
dc.subject.keywordCataract Extractionspa
dc.subject.keywordFeasibility Studiesspa
dc.subject.keywordFemalespa
dc.subject.keywordHumansspa
dc.subject.keywordInjectionsspa
dc.subject.keywordMacular Edemaspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle Agedspa
dc.subject.keywordPilot Projectsspa
dc.subject.keywordPostoperative Complicationsspa
dc.subject.keywordPseudophakiaspa
dc.subject.keywordRetreatmentspa
dc.subject.keywordRetrospective Studiesspa
dc.subject.keywordSouth Americaspa
dc.subject.keywordTomographyspa
dc.subject.keywordOptical Coherencespa
dc.subject.keywordVascular Endothelial Growth Factor Aspa
dc.subject.keywordVisual Acuityspa
dc.subject.keywordVitreous Bodyspa
dc.titlePrimary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema Pilot study of the Pan-American Collaborative Retina Study Groupspa
dc.title.TranslatedTitlePilot study of the Pan-American Collaborative Retina Study Groupeng
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos